Intrahepatic Cholestasis of Pregnancy Clinical Trials

Find Intrahepatic Cholestasis of Pregnancy Clinical Trials Near You

Bile Acids Metabolism and Genetic Mutation Profile in the Etiopathogenesis of Intrahepatic Cholestasis of Pregnancy in Indian Population- A Prospective Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Intrahepatic cholestasis of pregnancy (ICP) is a disorder characterized by itching, elevated fasting serum bile acids ≥10μmol/L (and elevated serum transaminases), with increased risks of perinatal complications, including spontaneous preterm labor, fetal distress, infant respiratory distress syndrome, meconium-stained liquor (MSL), and sudden intrauterine death (IUD). The Incidence of ICP varies from 0.1 to 15.6% of all pregnancies, with the highest cases in Chile, South Asia, America, and Scandinavia. The burden of ICP in India according to various states is as follows Punjab (3.1%), Chandigarh (4.8%), Delhi (0.79%), West Bengal (3.3%), and Lucknow (Uttar Pradesh) (2.8%).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 21
Maximum Age: 45
Healthy Volunteers: t
View:

• Age \> 21 years with consistent pruritus

• Characterized by consistent pruritus associated with elevated levels of serum transaminases (ALT \> 40 U/L or AST \> 37 U/L) or raised total serum bile acids (≥ 10 µmol/L)

• Able to understand and comply with the requirements of the study and voluntarily agrees to participate in the study by giving written informed consent before any study-related activity is performed

• Voluntary informed consent to participate until their delivery and also willing to be followed until their delivery

• Agrees to provide information on perinatal and maternal outcomes at or after delivery

Locations
Other Locations
India
Dr. Madhumita Premkumar
RECRUITING
Chandigarh
Contact Information
Primary
Dr Madhumita Premkumar, DM
drmadhumitap@gmail.com
7087003409
Backup
Jasvinder Nain, MPH
jasvindernain1506@gmail.com
Time Frame
Start Date: 2022-12-08
Estimated Completion Date: 2026-07
Participants
Target number of participants: 150
Treatments
Pregnant women with ICP
Case: Pregnant women with consistent pruritus or on medication for pruritus associated with an elevated level of serum transaminase alanine transaminase(ALT)\>40 IU/L or aspartate transaminase(AST)\>37 IU) and raised serum bile acids ≥10µmol/L will be eligible for the inclusion in the study.
Pregnant women without ICP
Controls: Healthy pregnant women of the same gestational age with routine physical examinations will be enrolled as a control group.
Sponsors
Leads: Post Graduate Institute of Medical Education and Research, Chandigarh

This content was sourced from clinicaltrials.gov